AstraZeneca’s Type 2 Diabetes Treatment Shows Clinical Benefit In Adolescents
AstraZeneca Plc (NASDAQ:AZN) has reported results from the Phase 3 trial evaluating exenatide extended-release 2mg in adolescents aged 10–17 years with…
AstraZeneca Says Phase III pivotal trial of once weekly exenatide in adolescents aged 10–17 shows benefit for the treatment of type 2 diabetes
Positive results from the Phase III pivotal trial (NCT01554618) showed AstraZeneca's exenatide extended-release 2mg once weekly significantly reduced blood sugar—as measured by HbA1c—versus placebo in
New Cannabinoid-Based Drug Candidates from Artelo Biosciences Show Promise as Cancer and Mental Health Treatments; Key Data Due Before Year End
The following article is sponsored by the clinical communications unit of Redington, Inc. The information contained in this article in no way represents investment advice or opinion on the part of Benzinga or its writers and is intended for informational purposes only.
The Daily Biotech Pulse: Lilly Spikes On Alzheimer’s Drug Regulatory Filing Plan, Applied Genetics, Arcus Issue Data Readouts, Adcom Test Awaits Incyte, Monte Rosa Prices IPO
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 23)
14 Biotech Stocks To Watch Over The Next 6 Months
Biotechs are at the mercy of several make-or-break catalysts that invariably have a big impact on stocks.
AstraZeneca Announced Orpathys Approved in China for Lung Cancer
AstraZeneca (NYSE: AZN) and HUTCHMED's (NASDAQ: HCM) Orpathys (savolitinib) has been granted conditional approval in China to treat patients with non-small cell lung cancer (NSCLC) with MET exon 14 skipping alterations who have progressed following prior syste